Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia

Daniel J. DeAngelo, Alison R. Walker, Richard F. Schlenk, Jorge Sierra, Bruno C. Medeiros, Enrique M. Ocio, Christoph Röllig, Stephen A. Strickland, Felicitas Thol, Sue zette Valera, Kohinoor Dasgupta, Noah Berkowitz, Robert K. Stuart

Research output: Contribution to journalArticleResearch

1 Citation (Scopus)

Abstract

© 2019 The role of histone deacetylase inhibitors in the treatment of acute myeloid leukemia (AML) is not well characterized. The current study evaluated the safety and efficacy of panobinostat in combination with idarubicin and cytarabine in newly diagnosed patients aged ≤65 years with primary or secondary high-risk AML based on cytogenetic classification. Treatment included fixed dose idarubicin (12 mg/m2/d, IV; day 1–3) and cytarabine (100 mg/m2/d, continuous IV infusion; day 1–7) and escalating oral doses of panobinostat at 15 mg, 20 mg, and 25 mg, thrice weekly starting at week 2 of a 28-day cycle. Forty-six patients were enrolled (primary AML [n = 36], secondary AML [n = 10]). The median age was 55 years. The most common all-grade AEs were diarrhea (54.3%), nausea (39.1%), vomiting, and decreased appetite (each, 21.7%), stomatitis (19.6%), and fatigue (17.4%). The overall response rate was 60.9%, 43.5% achieved a complete remission (CR), and 17.4% achieved CR with incomplete count recovery. The event-free survival at 1-year was 78.3%. Panobinostat in combination with idarubicin and cytarabine demonstrated tolerable safety and efficacy in younger patients with high-risk AML. The recommended phase 2 dose of panobinostat in this combination was 20 mg. ClinicalTrials.gov registry no: NCT01242774, and European Trial Registry EudraCT no: 2009-016809-42.
Original languageEnglish
Article number106197
JournalLeukemia Research
Volume85
DOIs
Publication statusPublished - 1 Oct 2019

Keywords

  • Acute myeloid leukemia
  • AML
  • Cytarabine
  • Idarubicin
  • Panobinostat

Fingerprint Dive into the research topics of 'Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J., Medeiros, B. C., Ocio, E. M., Röllig, C., Strickland, S. A., Thol, F., Valera, S. Z., Dasgupta, K., Berkowitz, N., & Stuart, R. K. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 85, [106197]. https://doi.org/10.1016/j.leukres.2019.106197